moomoo ID:NaN
Log Out
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
01951 Jinxin Fertility
Do not show
Hide blank lines
32.46% 1.14B 28.94% 1.84B 40.44% 859.3M -13.49% 1.43B
Operating income
32.46% 1.14B 28.94% 1.84B 40.44% 859.3M -13.49% 1.43B
Cost of sales
-35.86% -673.92M -24.07% -1.07B -25.78% -496.06M -3.44% -860.31M
Operating expenses
-35.86% -673.92M -24.07% -1.07B -25.78% -496.06M -3.44% -860.31M
Gross profit
27.82% 464.3M 36.36% 771.48M 67.04% 363.24M -30.73% 565.78M
Selling expenses
-105.47% -53.68M -49.23% -61.72M -67.71% -26.13M 33.53% -41.36M
Administrative expenses
-29.68% -187.6M -19.06% -327.73M -50.21% -144.66M -30.27% -275.26M
Research and development expenses
4.86% -4.74M 7.25% -10.65M -14.85% -4.98M 13.65% -11.48M
Special items of operating profit
57.08% 51.17M -5.64% 117.8M -42.23% 32.58M 358.31% 124.84M
Operating profit
22.46% 269.46M 34.94% 489.19M 39.60% 220.05M -34.94% 362.53M
Financing cost
-273.02% -32.99M -57.91% -21.15M -70.42% -8.85M -43.63% -13.39M
Share of profits of associates
65.16% -1.24M -- -6.82M -- -3.55M -- --
Share of profit from joint venture company
-80.37% -1.57M -- -3.29M -- -871K -- --
Earning before tax
13.00% 233.66M 31.16% 457.93M 35.65% 206.79M -36.28% 349.13M
-4.32% -46.06M -17.59% -104.23M -52.47% -44.16M 30.33% -88.64M
After-tax profit from continuing operations
15.35% 187.6M 35.78% 353.7M 31.70% 162.63M -38.08% 260.5M
Earning after tax
15.35% 187.6M 35.78% 353.7M 31.70% 162.63M -38.08% 260.5M
Minority profit
-136.55% -2.55M 55.47% 13.8M -5.49% 6.98M -19.72% 8.87M
Profit attributable to shareholders
22.17% 190.15M 35.08% 339.9M 34.07% 155.65M -38.57% 251.62M
Basic earnings per share
33.33% 0.08 40.00% 0.14 20.00% 0.06 -47.37% 0.1
Diluted earnings per share
16.67% 0.07 40.00% 0.14 20.00% 0.06 -47.37% 0.1
Currency Unit
Accounting Standards
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
--Deloitte Guan Huang Chen Fang Accountants--Deloitte Guan Huang Chen Fang Accountants

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The Group is the leading ARS supplier in China and the United States. According to the market research report on the Sino-US ARS market compiled by Frost Sullivan (Beijing) Consulting Co., Ltd. ("Frost Sullivan report"), the assisted reproductive medical institutions in the Group's Chinese network ranked third in China's ARS market in 2018, conducting 20958 IVF egg collection periods, accounting for about 3.1% of China's total market share. According to the same indicators, these institutions also ranked first among non-state-owned ARS suppliers in China in 2018. HRC Fertility (including HRC Medical managed by HRC Management under the Management Services Agreement) ranked No. 1 in the ARS market in the western United States in 2018. With the Group's leading position in the existing markets in the PRC and the United States, the Group is uniquely positioned to take advantage of the unmet needs of ARS patients in the PRC and the United States, as well as growth opportunities in both markets. The Group is committed to providing personalized solutions for patients to realize their dream of becoming parents. The Group has established a competitive advantage in brand, technology, medical team and management in markets with significant barriers to entry. All hospitals established within the Group's network are recognized as first-class in their respective regional markets, including, but not limited to, Sichuan Province, Greater Bay area, Yunnan Province and the western United States, which helps the Group to take a leading position in the ARS market in the PRC and the United States. In 2021, the Group acquired Jinxin Women and Children Hospital, Hong Kong Reproductive Health Centre (brand name: Thanksgiving Medical Centre) and Hong Kong assisted Fertility Centre to expand its footprint in Sichuan Province and the Greater Bay area and expand its scope of services to provide services during the whole reproductive period, including pregnancy preparation, IVF, prenatal, childbirth and postpartum services. In the first half of 2022, taking advantage of the Group's core business ARS services, the Group further expanded its service scope by integrating its ARS and obstetrics and gynaecology business to create synergies and increase its control over Zhongshan Hospital in Shenzhen. We believe that by making use of our existing resources and continuing to recruit talents and elites to join the Group, we will be able to successfully replicate the gains to the new areas we have entered. The Group expects that as the Chinese Government implements supportive policies and measures to encourage fertility (including the decision on optimizing the Fertility Policy to promote the long-term balanced Development of the population issued in July 2021), the penetration and market size of assisted reproductive services in China will increase significantly. Therefore, in order to seize the opportunities that have arisen, the Company made a number of acquisitions in 2021 and the first half of 2022, and the Group has developed a development strategy for the full reproductive period to prepare for the all-round development of ARS in China. The company aims to continuously expand its business network to benefit more people with high-quality ARS, which also helps to consolidate our leading position in the ARS market in China and the United States.
CEO: Yong Zhong
Market: Hong Kong motherboard
Listing Date: 06/25/2019
Hot List
SymbolLatest price%Chg